Determination of Circulating Tumor Cells by Flow Cytometry in the Bladder Cancer Patients

Crossmark: check for updates

Authors

  • Elif Ercan Department of Medical Biology, Ankara Yildirim Beyazit University, Faculty of Medicine, Ankara,Turkey
  • Ender Sımsek Department of Medical Biology, Ankara Yildirim Beyazit University, Faculty of Medicine, Ankara,Turkey
  • Ozen Ozensoy Guler Department of Medical Biology, Ankara Yildirim Beyazit University, Faculty of Medicine, Ankara,Turkey
  • Abdullah Erdem Canda Department of Urology, Ankara Yildirim Beyazit University, Faculty of Medicine, Ankara,Turkey; Department of Urology, Ankara Ataturk Training and Research Hospital, Ankara,Turkey
  • Ali Fuat Atmaca Department of Urology, Ankara Yildirim Beyazit University, Faculty of Medicine, Ankara,Turkey; Department of Urology, Ankara Ataturk Training and Research Hospital, Ankara,Turkey
  • Ahmet Carhan Department of Medical Biology, Ankara Yildirim Beyazit University, Faculty of Medicine, Ankara,Turkey

DOI:

https://doi.org/10.17140/UAOJ-2-115

Keywords:

Bladder cancer (Bca), Circulating tumor cells (CTCs), Flow cytometry

Abstract

Background
The current study aimed to detect of circulating tumor cells (CTCs) in 7.5 mL blood sample in bladder cancer patients treated with
transurethral resection (TUR) or radical cystectomy (RC) and compare the pre-operative and post-operative CTC counts.
Materials and Methods
CTCs were detected in peripheral blood of 10 bladder cancer patients with flow cytometry using biomarkers EpCAM, CK 14, 15, 16,
19 and CK 7, 8 for positive selection and CD45 for negative selection. The blood samples obtained before and after operation were
studied in 5 out of 10 patients.

Results

The CTC counts decreased significantly in patients (Z=2.032; p=0.042) after the operation. The pre-operative CTC counts for the
patient group were found to be significantly higher than the control group. No CTCs were detected in the control group.

Conclusion
The results are promising in terms of CTC detection in bladder cancer (Bca) by flow cytometry. Pre- and post-operative CTC counts
as predictive and prognostic biomarker dramatically change in this study.

References

Pecorino L. Molecular Biology of Cancer, Mechanisms, Targets and Therapeutics. 3rd ed. Oxford, UK: Oxford University Press; 2012.

Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol. 2011; 59: 997-1008. doi: 10.1016/j. eururo.2011.03.017

World Health Organization. Web site. http://www.who.int/ healthinfo/global-burden-disease/GBD-report-2004update-part2.pdf ?ua=1. Accessed October 12, 2017.

Fuessel S, Kunze D, Wirth MP. Bladder cancer biology. In: Canda AE, ed. Bladder Cancer - From basic science to Robotic Surgery. 1st ed. Rijeka, Croatia: InTech; 2010: 4-44.

Ferlay J, Soerjomataram I, Ervik M, et al. World cancer research fund international. 2012. London, UK. Web site. http://www.wcrf. org/int/cancer-facts-figures/worldwide-data. Accessed October 12, 2017.

Nezos A, Pissimisis N, Lembessis P, et al. Detection of circulating tumor cells in bladder cancer patients. Cancer Treat Rev. 2009; 35(3): 272-279. doi: 10.1016/j.ctrv.2008.11.003

Dawam D. Biomarkers of bladder cancer in urine: Evaluation of diagnostic and prognostic significance of current and potential markers. In: Canda AE, ed. Bladder Cancer-From Basic Science to Robotic Surgery. 1st ed. Rijeka, Croatia: InTech; 2012: 47-59.

Soave A, Riethdorf S, Pantel K, Fisch M, Rink M. Do circulating tumor cells have a role in deciding on adjuvant chemotherapy after radical cystectomy? Curr Urol Rep. 2015; 16(7): 46. doi: 10.1007/ s11934-015-0520-z

Konety BR. Molecular markers in bladder cancer: A critical appraisal. Urol Oncol. 2006; 24: 326-337. doi: 10.1016/j. urolonc.2005.11.023

Kinjo M, Okegawa T, Shigeo H, Kikuo N, Higashihara E. Detection of circulating MUC7-positive cells by reverse transcription-polymerase chain reaction in bladder cancer patients. Int J Urol. 2004; 11(1): 38-43.

Leotsakos I, Dimopoulos P, Gkioka E, et al. Detection of circulating tumor cells in bladder cancer using multiplex PCR assays. Anticancer Res. 2014; 34(12): 7415-7424.

Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: Approaches to isolation and characterization. J Cell Biol. 2011; 192(3): 373-382. doi: 10.1083/jcb.201010021.

Lowes LE, Allan AL. Recent advances in the molecular characterization of circulating tumor cells. Cancers (Basel). 2014; 6: 595-624. doi: 10.3390/cancers6010595

Hou HW, Warkiani ME, Khoo BL, et al. Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep. 2013; 3: 1259. doi: 10.1038/srep01259

Rosenberg R, Gertler R, Friederichs J, et al. Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry. 2002; 49(4): 150-158. doi: 10.1002/cyto.10161

Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: Clinical impact and future directions. Cancer Lett. 2007; 253: 180-204. doi: 10.1016/j.canlet.2006.12.014

Zabaglo L, Ormerod MG, Parton M, Ring A, Smith IE, Dowsett M. Cell filtration-laser scanning cytometry for the characterisation of circulating breast cancer cells. Cytometry A. 2003; 55(2): 102-108. doi: 10.1002/cyto.a.10071

Simsek E, Ozensoy Guler O, Carhan A, et al. The determination of circulating tumor cells in peripheral blood by flow cytometry. Niche. 2014; 3: 0-0. doi: 10.5152/niche.2015.246

Ross JS, Slodkowska EA. Circulating and disseminated tumor cells in the management of breast cancer. Am J Clin Pathol. 2009; 132(2): 237-245. doi: 10.1309/AJCPJI7DEOLKCS6F.

Allan AL, Keeney M. Circulating tumor cell analysis: Technical and statistical considerations for application to the clinic. J Oncol. 2010; 2010. doi: 10.1155/2010/426218

Deng G, Herrler M, Burgess D, Manna E, Krag D, Burke JF. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients. Breast Cancer Res. 2008; 10(4): R69. doi: 10.1186/bcr2131

Riethdorf S, Fritsche H, Müller V, et al. Detection of circulating Original Research | Volume 2 | Number 1| Carhan A, et al tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the CellSearch system. Clin Cancer Res. 2007; 13(3): 920-928. doi: 10.1158/1078-0432.CCR-06-1695

Alva A, Friedlander T, Clark M, et al. Circulating tumor cells as potential biomarkers in bladder cancer. J Urol. 2015; 194: 790-798. doi: 10.1158/1078-0432.CCR-06-1695

Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J. 1869; 14: 146-149.

Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 6th ed. New York, USA: Garland Science; 2015.

Balic M, Lin H, Williams A. Progress in circulating tumor cell capture and analysis: Implications for cancer management. Expert Rev. 2012; 12(3): 303-312. doi: 10.1586/erm.12.12

Zhang C, Guan Y, Sun Y, Ai D, Guo Q. Tumor heterogeneity and circulating tumor cells. Cancer Lett. 2016; 374(2): 216-223. doi: 10.1016/j.canlet.2016.02.024

Eccles SA, Aboagye EO, Ali S, et al. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013; 15(5): 92. doi: 10.1186/ bcr3493

Naoe M, Ogawa Y, Morita J, et al. Detection of circulating urothelial cancer cells in the blood using the CellSearch System. Cancer. 2007; 109: 1439-1445. doi: 10.1002/cncr.22543

Gallagher DJ, Milowsky MI, Ishill N, et al. Detection of circulating tumor cells in patients with urothelial cancer. Ann Oncol. 2008; 20(2): 305-308. doi: 10.1093/annonc/mdn627

Gazzaniga P, Gradilone A, de Berardinis E, et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: A cellsearch analysis. Ann Oncol. 2012; 23(9): 2352-2356. doi: 10.1093/annonc/mdr619

Nagata M, Muto S, Horie S. Molecular biomarkers in bladder cancer: Novel potential indicators of prognosis and treatment outcomes. Dis Markers. 2016. doi: 10.1155/2016/8205836

Rink M, Chun FKH, Minner S, et al. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int. 2011; 107: 1668-1675. doi: 10.1111/j.1464-410X.2010.09562.x.

Alkibay T, Gürocak S. Ürogenital tümörler. In: Anafarta K, Arıkan B, Bedük Y, ed. Temel Üroloji. 4th ed. Ankara, Turkey: Güneş Tıp Kitapevi; Solar Medical Book; 2011: 737-739.

Liu Z, Fusi A, Klopocki E, et al. Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J Transl Med. 2011; 9: 70. doi: 10.1186/1479-5876-9-70

Hong B, Zu Y. Detecting circulating tumor cells: Current challenges and new trends. Theranostics. 2013; 3(6): 377-394.

Downloads

Published

2018-06-22

How to Cite

Elif Ercan, Ender Sımsek, Ozen Ozensoy Guler, Abdullah Erdem Canda, Ali Fuat Atmaca, & Ahmet Carhan. (2018). Determination of Circulating Tumor Cells by Flow Cytometry in the Bladder Cancer Patients. Urology and Andrology , 2(1), 25–30. https://doi.org/10.17140/UAOJ-2-115

Issue

Vol. 2 No. 1 (2018): Volume 2 Issue 1 2018

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Urology and Andrology (UA) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.